327 results on '"Privitera G"'
Search Results
2. POS1172 PLASMA STREM1 AND IL-6 DETERMINATION IDENTIFY DISTINCT SUBSETS AND IMPROVE CLINICAL MANAGEMENT IN SPONDYLOARTHRITIS: A CROSS-SECTIONAL STUDY
- Author
-
Gremese, E., primary, Perniola, S., additional, Tolusso, B., additional, Mario, C. DI, additional, Parisio, L., additional, Campobasso, D., additional, Bruno, D., additional, Gessi, M., additional, Privitera, G., additional, Varca, S., additional, Benvenuto, R., additional, Guidi, L., additional, Alivernini, S., additional, and Pugliese, D., additional
- Published
- 2024
- Full Text
- View/download PDF
3. OC.07.8: THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
- Author
-
Del Gaudio, A., primary, Parisio, L., additional, Cuccia, G., additional, Privitera, G., additional, Laterza, L., additional, Lopetuso, L.R., additional, Rumi, G., additional, De Biasio, F., additional, Mignini, I., additional, Coppola, G., additional, Gasbarrini, A., additional, Scaldaferri, F., additional, and Pugliese, D., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Transport Conductivity of Graphene at RF and Microwave Frequencies
- Author
-
Awan, S. A., Lombardo, A., Colli, A., Privitera, G., Kulmala, T., Kivioja, J. M., Koshino, M., and Ferrari, A. C.
- Subjects
Condensed Matter - Mesoscale and Nanoscale Physics ,Condensed Matter - Materials Science - Abstract
We measure graphene coplanar waveguides from direct current (DC) to 13.5GHz and show that the apparent resistance (in the presence of parasitic impedances) has an quadratic frequency dependence, but the intrinsic conductivity (without the influence of parasitic impedances) is frequency-independent. Consequently, in our devices the real part of the complex alternating current conductivity is the same as the DC value and the imaginary part~0. The graphene channel is modelled as a parallel resistive-capacitive network with a frequency dependence identical to that of the Drude conductivity with momentum relaxation time~2.1ps, highlighting the influence of alternating current (AC) electron transport on the electromagnetic properties of graphene. This can lead to optimized design of high-speed analogue field-effect transistors, mixers, frequency doublers, low-noise amplifiers and radiation detectors.
- Published
- 2015
- Full Text
- View/download PDF
5. P715 Multiparametric assessment of IBD and SpA-IBD patients to explore disease biomarkers and response predictors
- Author
-
Privitera, G, primary, Parisio, L, additional, Perniola, S, additional, Varca, S, additional, Alivernini, S, additional, Tolusso, B, additional, Petito, V, additional, Napolitano, D, additional, Schiavoni, E, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, Armuzzi, A, additional, Gremese, E, additional, Guidi, L, additional, and Pugliese, D, additional
- Published
- 2024
- Full Text
- View/download PDF
6. P460 The POCER index: application of a novel endoscopic score in a real-life cohort of patients with Crohn's disease after surgery
- Author
-
Parisio, L, primary, Del Gaudio, A, additional, Privitera, G, additional, Cuccia, G, additional, Lopetuso, L R, additional, Laterza, L, additional, Rumi, G, additional, De Biasio, F, additional, Mignini, I, additional, Calvez, V, additional, Coppola, G, additional, Gasbarrini, A, additional, Scaldaferri, F, additional, and Pugliese, D, additional
- Published
- 2024
- Full Text
- View/download PDF
7. P1062 Effectiveness and safety outcomes beyond five years of IBD patients treated with vedolizumab. The LONG-LIVE IG-IBD study
- Author
-
Privitera, G, primary, Pugliese, D, additional, and Armuzzi, A, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Artificial Intelligence Chatbots for medical training in Public Health: a tool to explore
- Author
-
Baglivo, F, primary, De Angelis, L, additional, Casigliani, V, additional, Arzilli, G, additional, Privitera, G P, additional, and Rizzo, C, additional
- Published
- 2023
- Full Text
- View/download PDF
9. POS0441 SPONDYLOARTHRITIS IMMUNOLOGICAL AND TISSUES FEATURES DIFFER ACCORDING TO THE COHEXISTING INFLAMMATORY BOWEL DISEASE: A CROSS-SECTIONAL STUDY
- Author
-
Perniola, S., primary, Tolusso, B., additional, Di Mario, C., additional, Pugliese, D., additional, Bruno, D., additional, Gessi, M., additional, Parisio, L., additional, Privitera, G., additional, Guidi, L., additional, Alivernini, S., additional, and Gremese, E., additional
- Published
- 2023
- Full Text
- View/download PDF
10. PC.01.2 IL-33 ACTIVATES CD73-EXPRESSING CELLS PROMOTING TUMORIGENESIS DURING COLITIS-ASSOCIATED COLORECTAL CANCER
- Author
-
Lopetuso, L.R., primary, Privitera, G., additional, Di, Martino L., additional, Scaldaferri, F., additional, Gasbarrini, A., additional, Cominelli, F., additional, De Salvo, C., additional, and Pizarro, T.T., additional
- Published
- 2023
- Full Text
- View/download PDF
11. OC.10.5 ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
- Author
-
Pugliese, D., primary, Privitera, G., additional, and Armuzzi, A., additional
- Published
- 2023
- Full Text
- View/download PDF
12. P099 IL-33 activates CD73-expressing cells promoting tumorigenesis during colitis-associated colorectal cancer
- Author
-
Lopetuso, L R, primary, Privitera, G, additional, Di Martino, L, additional, Scaldaferri, F, additional, Gasbarrini, A, additional, Cominelli, F, additional, De Salvo, C, additional, and Pizarro, T, additional
- Published
- 2023
- Full Text
- View/download PDF
13. P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study
- Author
-
Dragoni, G, primary, Castiglione, F, additional, Bezzio, C, additional, Pugliese, D, additional, Spagnuolo, R, additional, Viola, A, additional, Cocomazzi, F, additional, Aratari, A, additional, Savarino, E V, additional, Balestrieri, P, additional, Onali, S, additional, Viganò, C, additional, Ribaldone, D G, additional, Innocenti, T, additional, Testa, A, additional, Saibeni, S, additional, Privitera, G, additional, Milla, M, additional, Armuzzi, A, additional, Fantini, M C, additional, and Fiorino, G, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases
- Author
-
Goessens, L., Colombel, J. -F., Outtier, A., Ferrante, M., Sabino, J., Judge, C., Saeidi, R., Rabbitt, L., Armuzzi, A., Domenech, E., Michalopoulos, G., Cremer, A., Garcia-Alonso, F. J., Molnar, T., Karmiris, K., Gecse, K., Van Oostrom, J., Lowenberg, M., Farkas, K., Atreya, R., Ribaldone, D. G., Selinger, C., Hoentjen, F., Bihin, B., Sebastian, S., Rahier, J. -F., Baert, F., Horin, S. B., Bossuyt, P., Mas, E. B., Buckley, M., Byron, C., Coe, C., Doherty, G. A., Dragoni, G., Fernandes, S., Gaya, D. P., Gleeson, S., Keogh, A., Levine, A., Ortega, T. L., Lobo, A. J., Macken, E., Mccarthy, J., Noor, N., O'Toole, A., Posen, A., Privitera, G., Pugliese, D., Raine, T., Reenaers, C., Resal, T., Scarcelli, A., Slattery, E., Strubbe, B., Sugrue, K., Groen, M. T., Vicente, G. T., Truyens, M., Viola, A., Yanai, H., Zulquernain, S. A., Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Unité de support scientifique
- Subjects
Adult ,Male ,safety ,medicine.medical_specialty ,Combination therapy ,Adolescent ,Opportunistic infection ,Inflammatory bowel disease ,combination therapy ,Young Adult ,Interquartile range ,inflammatory bowel disease ,Internal medicine ,Medicine ,Humans ,biologics ,Adverse effect ,Retrospective Studies ,Biological Products ,treatment ,business.industry ,immune mediated inflammatory disease ,Gastroenterology ,Retrospective cohort study ,medicine.disease ,Inflammatory Bowel Diseases ,Europe ,small molecules ,Oncology ,Immune-mediated inflammatory diseases ,Original Article ,Drug Therapy, Combination ,Female ,Skin cancer ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] - Abstract
BACKGROUND AND AIMS: Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. METHODS: Combination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the occurrence of serious infection, opportunistic infection, hospitalisation, life-threatening event, worsening of IBD or immune-mediated inflammatory diseases (IMID), cancer and death. Efficacy was evaluated as the physician global assessment of the combination and comparison of clinical/endoscopic scores of IBD/IMID activity prior and during combination. RESULTS: A total of 104 combinations were collected in 98 patients. Concomitant IMID were present in 41 patients. Reasons for starting combination therapy were active IBD (67%), active IMID or extra-intestinal manifestations (EIM) (22%), both (10%) and unclassified in 1. Median duration of combination was 8 months (interquartile range 5-16). During 122 patient-years of follow-up, 42 significant adverse events were observed, mostly related to uncontrolled IBD. There were 10 significant infections, 1 skin cancer and no death. IBD disease activity was clinically improved in 70% and IMID/EIM activity in 81% of the patients. Overall, combination was continued in 55% of the patients. CONCLUSIONS: Combination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%. ispartof: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL vol:9 issue:10 pages:1136-1147 ispartof: location:England status: published
- Published
- 2021
15. Need for a competency-based approach for the Public Health Workforce training: the ISS proposal
- Author
-
Mazaccara, A, primary, Privitera, G, additional, Di Pucchio, A, additional, Barbina, D, additional, Bertinato, L, additional, Mistretta, A, additional, Simonelli, M, additional, Caminada, S, additional, Arzilli, G, additional, and Brusaferro, S, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Flu vaccination coverage in healthcare workers during a 3-year period in the context of the pandemic
- Author
-
Scardina, G, primary, Ceccarelli, L, additional, Casigliani, V, additional, Mazzilli, S, additional, Padovan, M, additional, Petillo, A, additional, Tavoschi, L, additional, Foddis, R, additional, Privitera, G, additional, and Baggiani, A, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study
- Author
-
Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.
- Subjects
Crohn’s disease ,Ulcerative ,Antibodies, Monoclonal, Humanized ,biologics (IBD) ,immunosuppression ,ulcerative colitis ,Aged ,Chronic Disease ,Colitis, Ulcerative ,Crohn Disease ,Humans ,Prospective Studies ,Retrospective Studies ,Treatment Outcome ,Tumor Necrosis Factor Inhibitors ,Gastrointestinal Agents ,Inflammatory Bowel Diseases ,Antibodies ,Monoclonal ,Pharmacology (medical) ,Humanized ,Settore MED/12 - Gastroenterologia ,Hepatology ,Gastroenterology ,Colitis - Abstract
Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.
- Published
- 2022
18. In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2
- Author
-
Privitera, G., Luca, T., Musso, N., Vancheri, C., Crimi, N., Barresi, V., Condorelli, D., and Castorina, S.
- Published
- 2016
- Full Text
- View/download PDF
19. OC.17.4 COMBINATION OF ADVANCED THERAPIES IN PATIENTS WITH COMPLEX INFLAMMATORY BOWEL DISEASE
- Author
-
Privitera, G., primary, Parisio, L., additional, Pugliese, D., additional, Onali, S., additional, Settanni, C.R., additional, Scaldaferri, F., additional, Gasbarrini, A., additional, Guidi, L., additional, and Armuzzi, A., additional
- Published
- 2022
- Full Text
- View/download PDF
20. The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications
- Author
-
Scaldaferri, F., Ianiro, G., Privitera, G., Lopetuso, L. R., Vetrone, L. M., Petito, V., Pugliese, D., Neri, M., Cammarota, G., Ringel, Y., Costamagna, G., Gasbarrini, A., Boskoski, I., Armuzzi, A., Scaldaferri F. (ORCID:0000-0001-8334-7541), Ianiro G. (ORCID:0000-0002-8318-0515), Privitera G., Lopetuso L. R., Vetrone L. M., Petito V., Pugliese D., Neri M., Cammarota G. (ORCID:0000-0002-3626-6148), Costamagna G. (ORCID:0000-0002-8100-2731), Gasbarrini A. (ORCID:0000-0002-7278-4823), Boskoski I. (ORCID:0000-0001-8194-2670), Armuzzi A. (ORCID:0000-0003-1572-0118), Scaldaferri, F., Ianiro, G., Privitera, G., Lopetuso, L. R., Vetrone, L. M., Petito, V., Pugliese, D., Neri, M., Cammarota, G., Ringel, Y., Costamagna, G., Gasbarrini, A., Boskoski, I., Armuzzi, A., Scaldaferri F. (ORCID:0000-0001-8334-7541), Ianiro G. (ORCID:0000-0002-8318-0515), Privitera G., Lopetuso L. R., Vetrone L. M., Petito V., Pugliese D., Neri M., Cammarota G. (ORCID:0000-0002-3626-6148), Costamagna G. (ORCID:0000-0002-8100-2731), Gasbarrini A. (ORCID:0000-0002-7278-4823), Boskoski I. (ORCID:0000-0001-8194-2670), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a direct impact on the gastrointestinal system, as up to 50% of fecal samples from coronavirus disease 2019 (COVID-19) patients contain detectable viral RNA despite a negative rhino-pharyngeal swab. This finding, together with an intestinal expression of angiotensin conversion enzyme 2 protein, suggests a possible fecal-oral transmission for SARSCoV-2. Furthermore, gastrointestinal (GI) symptoms are common in COVID-19 patients including watery diarrhea, vomiting particularly in children nausea, and abdominal pain. Pathogenesis of SARS-CoV-2 infection presents significant similarities to those of some immune-mediated diseases, such as inflammatory bowel diseases or rheumatoid arthritis, leading to the hypothesis that targeted therapies used for the treatment of immune-mediated disease could be effective to treat (and possibly prevent) the main complications of COVID-19. In this review, we synthesize the present and future impact of SARS-CoV-2 infection on the gastrointestinal system and on gastroenterology practice, hypothesizing a potential role of the "gut-lung axis" and perhaps of the gut and lung microbiota into the interindividual differential susceptibility to COVID-19 19 disease. Finally, we speculate on the reorganization of outpatient gastroenterology services, which need to consider, among other factors, the major psychological impact of strict lockdown measures on the whole population.
- Published
- 2020
21. Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal Cancer
- Author
-
Privitera, Giuseppe, Rana, N., Scaldaferri, Franco, Armuzzi, Alessandro, Pizarro, T. T., Privitera G., Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Rana, N., Scaldaferri, Franco, Armuzzi, Alessandro, Pizarro, T. T., Privitera G., Scaldaferri F. (ORCID:0000-0001-8334-7541), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Colorectal cancer (CRC) is one of the most prevalent and deadly forms of cancer in Western countries. Inflammation is a well-known driver of colonic carcinogenesis; however, its role in CRC extends beyond colitis-associated cancer. Over the last decades, numerous associations between intestinal dysbiosis and CRC have been identified, with more recent studies providing mechanistic evidence of a causative relationship. Nonetheless, much remains to be discovered regarding the precise implications of microbiome alterations in the pathogenesis of CRC. Research confirms the importance of a bidirectional crosstalk between the gut microbiome and the mucosal immune system in which inflammasomes, multiprotein complexes that can sense “danger signals,” serve as conduits by detecting microbial signals and activating innate immune responses, including the induction of microbicidal activities that can alter microbiome composition. Current evidence strongly supports an active role for this “inflammasome–microbiome axis” in the initiation and development of CRC. Furthermore, the gasdermin (GSDM) family of proteins, which are downstream effectors of the inflammasome that are primarily known for their role in pyroptosis, have been recently linked to CRC pathogenesis. These findings, however, do not come without controversy, as pyroptosis is reported to exert both anti- and protumorigenic functions. Furthermore, the multi-faceted interactions between GSDMs and the gut microbiome, as well as their importance in CRC, have only been superficially investigated. In this review, we summarize the existing literature supporting the importance of the inflammasome–microbiota axis, as well as the activation and function of GSDMs, to gain a better mechanistic understanding of CRC pathogenesis.
- Published
- 2022
22. The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic
- Author
-
Napolitano, Daniele, Galasso, Linda, Privitera, Giuseppe, Morana, G., Bardelli, A., Sinatora, R., Onidi, M. F., Lombardi, M. T., Orgiana, N., Amatucci, V., Strazzeri, M., Schiavoni, Elisa, Turchini, Laura, Guarini, Antonella, Settanni, Carlo Romano, Armuzzi, Alessandro, Scaldaferri, Franco, Napolitano D., Galasso L., Privitera G., Schiavoni E., Turchini L., Guarini A., Settanni C. R., Armuzzi A. (ORCID:0000-0003-1572-0118), Scaldaferri F. (ORCID:0000-0001-8334-7541), Napolitano, Daniele, Galasso, Linda, Privitera, Giuseppe, Morana, G., Bardelli, A., Sinatora, R., Onidi, M. F., Lombardi, M. T., Orgiana, N., Amatucci, V., Strazzeri, M., Schiavoni, Elisa, Turchini, Laura, Guarini, Antonella, Settanni, Carlo Romano, Armuzzi, Alessandro, Scaldaferri, Franco, Napolitano D., Galasso L., Privitera G., Schiavoni E., Turchini L., Guarini A., Settanni C. R., Armuzzi A. (ORCID:0000-0003-1572-0118), and Scaldaferri F. (ORCID:0000-0001-8334-7541)
- Abstract
Background: During the COVID-19 pandemic, many inflammatory bowel disease (IBD) centres had to reorganise their work, and multidisciplinary teams, including IBD nurses, have had to try to deliver services to patients as safely as possible. Aims: This survey aimed to assess the thoughts, opinions and feelings of IBD patients on biologics regarding the efforts of IBD nurses to organise care during the COVID-19 pandemic. Methods: An evaluation survey based on an anonymous questionnaire was distributed to IBD nurses in five Italian IBD centres, in parallel. Findings: Of 306 participants, 55.6% had Crohn’s disease and 44.4% had ulcerative colitis. Most (79.1%) were aware of the specialist IBD nurse role, and 75.8% could distinguish it from generalist nurses. Of patients, 99.7% felt IBD nurses were competent to care for their condition and 91.2% felt that IBD nurses could provide valid scientific information. Meanwhile, 81.4% had a good or excellent relationship with their IBD nurse. Patients reported that most nurses wore personal protective equipment (94.4%), promoted self-care (91.8%), asked about presence of fever or cough (84.3%), asked about patient health status (83.7%) and covered pandemic safety and social distancing rules (69.3%), but fewer spoke about patient mood (44.4%) or relevant benefits, rules and exemptions (26.8%). Most participants (77.8%) faced pandemic-related issues for infusions. Nearly all (97.4%) knew immunosuppressed people were vulnerable to COVID-19, but only 42.8% spoke to their nurse about it. Some 61.8% of patients were concerned about COVID-19, but only 39.2% raised this with the IBD nurse. However, many more patients spoke to a nurse about concerns regarding biologics (41.8%) and worsening IBD symptoms (46.4%) in the pandemic than the actual number experiencing these issues (13.7% and 4.3%, respectively). Conclusion: The results show that IBD patients appreciate the role of the specialist nurse in their care.
- Published
- 2022
23. GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis
- Author
-
Rana, N. Privitera, G. Kondolf, H.C. Bulek, K. Lechuga, S. De Salvo, C. Corridoni, D. Antanaviciute, A. Maywald, R.L. Hurtado, A.M. Zhao, J. Huang, E.H. Li, X. Chan, E.R. Simmons, A. Bamias, G. Abbott, D.W. Heaney, J.D. Ivanov, A.I. Pizarro, T.T.
- Abstract
Gasdermins are a family of structurally related proteins originally described for their role in pyroptosis. Gasdermin B (GSDMB) is currently the least studied, and while its association with genetic susceptibility to chronic mucosal inflammatory disorders is well established, little is known about its functional relevance during active disease states. Herein, we report increased GSDMB in inflammatory bowel disease, with single-cell analysis identifying epithelial specificity to inflamed colonocytes/crypt top colonocytes. Surprisingly, mechanistic experiments and transcriptome profiling reveal lack of inherent GSDMB-dependent pyroptosis in activated epithelial cells and organoids but instead point to increased proliferation and migration during in vitro wound closure, which arrests in GSDMB-deficient cells that display hyper-adhesiveness and enhanced formation of vinculin-based focal adhesions dependent on PDGF-A-mediated FAK phosphorylation. Importantly, carriage of disease-associated GSDMB SNPs confers functional defects, disrupting epithelial restitution/repair, which, altogether, establishes GSDMB as a critical factor for restoration of epithelial barrier function and the resolution of inflammation. © 2021 Elsevier Inc.
- Published
- 2022
24. Igiene, Medicina Preventiva, Sanità Pubblica
- Author
-
Barbuti, S, Fara, Gm, Giammanco, G, Azara, Aa, Baldo, V, Borella, P, Castiglia, Pg, Coniglio, Ma, Contu, P, Delia, Sa, Donato, F, Faggiano, F, Gabutti, G, Icardi, G, Izzotti, A, Laganà, P, Montagna, Mt, Napoli, C, Orsi, Gb, Privitera, G, Pulliero, A, Sardu, C, Stracci, F, and Vinceti, M
- Published
- 2022
25. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
- Author
-
Guidi, L., Pugliese, D., Tonucci, T. P., Bertani, L., Costa, F., Privitera, G., Tolusso, B., Di Mario, C., Albano, E., Tapete, G., Gremese, E., Papa, A., Gasbarrini, A., Rapaccini, G. L., Armuzzi, A., Guidi L. (ORCID:0000-0003-3320-7094), Pugliese D., Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Di Mario C., Gremese E. (ORCID:0000-0002-2248-1058), Papa A. (ORCID:0000-0002-4186-7298), Gasbarrini A. (ORCID:0000-0002-7278-4823), Rapaccini G. L. (ORCID:0000-0002-6467-857X), Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi, L., Pugliese, D., Tonucci, T. P., Bertani, L., Costa, F., Privitera, G., Tolusso, B., Di Mario, C., Albano, E., Tapete, G., Gremese, E., Papa, A., Gasbarrini, A., Rapaccini, G. L., Armuzzi, A., Guidi L. (ORCID:0000-0003-3320-7094), Pugliese D., Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Di Mario C., Gremese E. (ORCID:0000-0002-2248-1058), Papa A. (ORCID:0000-0002-4186-7298), Gasbarrini A. (ORCID:0000-0002-7278-4823), Rapaccini G. L. (ORCID:0000-0002-6467-857X), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Background: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. Objective: The purpose of this study was to evaluate in a prospective observational study the utility of an early vedolizumab trough level assay for predicting the first-year vedolizumab therapy outcome. Methods: This prospective observational study included consecutive inflammatory bowel disease patients. We measured vedolizumab trough levels and anti-vedolizumab antibodies at weeks 6 and 14. Clinical outcome was assessed at weeks 6, 14, 22 and 54. The primary endpoint was the correlation between early vedolizumab trough levels and vedolizumab persistence over the first year of treatment, defined as the maintenance of vedolizumab therapy due to sustained clinical benefit. Results: We included 101 patients initiating vedolizumab. A cut-off vedolizumab trough level of 16.55 µg/ml at week 14 predicted vedolizumab persistence within the first year of therapy, with 73.3% sensitivity and 59.4% specificity (p = 0.0009). Week 14 vedolizumab trough level was significantly higher in patients with clinical remission at weeks 14, 22 and 54; and in patients achieving mucosal healing within 54 weeks. Conclusion: High vedolizumab trough level at week 14 was associated with a higher probability of maintaining vedolizumab therapy over the first year due to sustained clinical benefit.
- Published
- 2019
26. 'My body is out to wreck everything I have': A qualitative study of how women with endometriosis feel about their bodies
- Author
-
Jacqueline Mills, Rush-Privitera G, Shu C, and Misajon R
- Subjects
business.industry ,Endometriosis ,medicine ,Artificial intelligence ,Thematic analysis ,medicine.disease ,business ,Psychology ,computer.software_genre ,computer ,Natural language processing - Abstract
There is a distinct lack of research regarding the relationship with the body in women with endometriosis, despite the condition involving significant changes to appearance and impaired bodily functionality. The current study aimed to understand how women with endometriosis feel about their body. Participants completed an online survey with open-ended questions on how they feel about their body, physical appearance, and level of daily functioning. Responses from 315 women with endometriosis were analysed using reflexive thematic analysis, generating three themes: 1) “It makes me feel broken and inadequate” (Sense of being defective); 2) “I feel like I’m in a war with it” (Sense of conflict); and 3) “I feel like my body isn’t mine; it’s out of control” (Sense of alienation). The findings provide support for the notion that the relationship between the body and sense of self is particularly problematic for women with endometriosis and warrants therapeutic intervention. Future research should verify the efficacy of appreciation and self-compassion-based interventions for women with endometriosis.
- Published
- 2021
27. Digital devices to assess vaccine hesitancy and promote pertussis vaccination during pregnancy
- Author
-
Arzilli, G, primary, Scardina, G, additional, Menicagli, D, additional, Lucaccini, E, additional, Sironi, D, additional, Papini, F, additional, Tavoschi, L, additional, Lopalco, PL, additional, and Privitera, G, additional
- Published
- 2021
- Full Text
- View/download PDF
28. OC.09.1 THE MODERATING EFFECT OF RESILIENCE ON DEPRESSION IN PATIENTS WITH CROHN’S DISEASE
- Author
-
Ferrarese, D., primary, Belella, D., additional, Vecchione, M., additional, Spagnolo, G., additional, Petito, C., additional, Scaldaferri, F., additional, Pugliese, D., additional, Privitera, G., additional, Addolorato, G., additional, Chieffo, D.P.R., additional, Gasbarrini, A., additional, and Armuzzi, A., additional
- Published
- 2021
- Full Text
- View/download PDF
29. OC.09.3 EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND YOUNG IBD PATIENTS: IG IBD LIVE STUDY GROUP
- Author
-
Pugliese, D., primary, Privitera, G., additional, and Armuzzi, A., additional
- Published
- 2021
- Full Text
- View/download PDF
30. Assessment, control, and prevention of microbiological and chemical hazards in seasonal swimming pools of the Versilia district (Tuscany, central Italy)
- Author
-
Totaro M.[1], Vaselli O.[2, Nisi B.[4], Frendo L.[1], Cabassi J.[3], Profeti S.[1], Valentini P.[1], Casini B.[1], Privitera G.[1], and Baggiani A. [1]
- Subjects
Microbiology (medical) ,0208 environmental biotechnology ,02 engineering and technology ,010501 environmental sciences ,01 natural sciences ,Analysis ,Disinfection procedures ,Microbiological and chemical hazards ,Swimming pools ,Water sampling ,swimming pools ,medicine ,Waste Management and Disposal ,0105 earth and related environmental sciences ,Water Science and Technology ,disinfection procedures ,Public Health, Environmental and Occupational Health ,Waterborne diseases ,microbiological and chemical hazards ,medicine.disease ,water sampling and analysis ,020801 environmental engineering ,Disinfection ,Infectious Diseases ,Italy ,Environmental chemistry ,Environmental science ,Christian ministry ,Seawater ,Seasons ,Water quality ,Water Pollutants, Chemical ,Disinfectants - Abstract
Although in Europe the quality of swimming pools (SPs) is dictated by regulations, microbiological and chemical hazards are described in the literature. Environmental bacteria or toxic disinfection by-product (DBP) compounds may indeed be recovered in waters even after disinfection. We evaluated the water quality from 26 outdoor seasonal SPs of the Versilia district, according to requirements of Regional Decree 54R/2015. In spring 2017, supply and reinstatement waters were collected after shock hyperchlorination (10 mg/L) while in summertime, a second sampling of waters before entering the pools, as well as in the pools, was performed after SPs were open to the public. In all samples, microbiological and chemical parameters were determined as defined by Directive 98/83/EC and the Italian Health Ministry. Microbiological data were within suggested limits. The first chemical analyses showed that in 35% of the feeding-pool seawater samples, the halogenated organic compounds were higher than the maximum permissible concentrations (30 μg/L). Pool waters were then dechlorinated and re-treated with hydrogen peroxide (10 mg/L) to ensure the abatement of DBPs (from 164 ± 107 to 0.9 ± 0.8 μg/L; p = 0.002). Results highlighted the need of self-controlled procedures for the SPs waters to prevent waterborne diseases and suggested hydrogen peroxide as the most appropriate disinfection method.
- Published
- 2019
31. DOP49 Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group
- Author
-
Pugliese, D, primary, Privitera, G, additional, and Armuzzi, A, additional
- Published
- 2021
- Full Text
- View/download PDF
32. Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients
- Author
-
Bertani, L, Tricò, D, Pugliese, D, Privitera, G, Linsalata, G, Zanzi, F, Mumolo, Mg, Barberio, B, Monzani, F, Marchi, S, Guidi, L, Blandizzi, C, Armuzzi, A, and Costa, F
- Published
- 2021
33. Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study
- Author
-
Pugliese, D, Privitera, G, Rogai, F, Variola, A, Viola, A, Laterza, L, Privitera, Ac, Allocca, M, Bossa, F, Cappello, M, Daperno, M, Lorenzon, G, Mazzuoli, S, Principi, M, Sablich, R, Moser, L, Ferronato, A, Traini, S, Tapete, G, Bodini, G, Di Girolamo, M, Grossi, L, Mocci, G, Ricci, C, Saibeni, S, Festa, S, Spagnuolo, R, Cortelezzi, Cc, Mocciaro, F, Rizzello, F, Armuzzi, A, and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD
- Subjects
remission ,naïve ,persistence ,Golimumab ,ulcerative colitis - Published
- 2021
34. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
- Author
-
Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Pugliese, Daniela, Guidi, Luisa, Privitera, Giuseppe, Bertani, L., Tolusso, Barbara, Papparella, Luigi Giovanni, Maltinti, S., Di Mario, Clara, Onali, Sebastiano, Ceccarelli, L., Rapaccini, Gian Ludovico, Scaldaferri, Franco, Gremese, Elisa, Gasbarrini, Antonio, Costa, F., Armuzzi, Alessandro, Pugliese D., Guidi L. (ORCID:0000-0003-3320-7094), Privitera G., Tolusso B. (ORCID:0000-0002-9108-6609), Papparella L. G., Di Mario C., Onali S., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Scaldaferri F. (ORCID:0000-0001-8334-7541), Gremese E. (ORCID:0000-0002-2248-1058), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Background: Switching from IFX originator to CT-P13 is safe; however, little data on immunogenicity exists. Research design and methods: Consecutive IBD patients on IFX originator were switched to CT-P13 and followed-up for 12 months. Clinical activity, infliximab trough levels (ITLs), anti-drug antibodies (ATIs), and adverse events were recorded at predefined timepoints (baseline, second CT-P13 infusion, 6 and 12 months). The outcomes investigated were immunogenicity, pharmacokinetics, effectiveness and safety. Results: 119 patients were switched to CT-P13 after a median time with IFX of 5.8 years. No changes in mean ITLs were observed. ATIs were detected in 30 patients (25.2%): 14 before and 16 after switch. Mean persistent ATIs were significantly higher compared to mean transient ones (109.74 ng/mL ±84.70 vs 18.22 ng/mL ±11.37, p < 0.001), with significantly lower ITLs associated (mean 0.32 µg/mL ±0.6 vs 3.08 µg/mL ±3.22, p < 0.001). A significant decrease of patients in steroid-fee clinical remission was observed after the switch (p = 0.004), with subsequent improvement at 6 months (p = 0.005). Eighteen patients (15.1%) discontinued IFX, only 6 (5%) for loss of response. Conclusions: Switching from infliximab originator to CT-P13 seems safe and effective, without differences in immunogenicity. A temporary reduction of clinical benefit after switching could be potentially explained by a ‘nocebo-effect response’.
- Published
- 2021
35. The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19
- Author
-
Napolitano, Daniele, Privitera, Giuseppe, Schiavoni, Elisa, Turchini, Laura, Amatucci, V., Pugliese, Daniela, Gasbarrini, Antonio, Scaldaferri, Franco, Armuzzi, Alessandro, Napolitano D., Privitera G., Schiavoni E., Turchini L., Pugliese D., Gasbarrini A. (ORCID:0000-0002-7278-4823), Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), Napolitano, Daniele, Privitera, Giuseppe, Schiavoni, Elisa, Turchini, Laura, Amatucci, V., Pugliese, Daniela, Gasbarrini, Antonio, Scaldaferri, Franco, Armuzzi, Alessandro, Napolitano D., Privitera G., Schiavoni E., Turchini L., Pugliese D., Gasbarrini A. (ORCID:0000-0002-7278-4823), Scaldaferri F. (ORCID:0000-0001-8334-7541), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
OBJECTIVE: The role of nurses has great educational-scientific potential in COVID-19 vaccination. The aim of this work is to clarify whether the educational role of IBD nurses in vaccination is perceived by IBD patients. MATERIALS AND METHODS: A cross-sectional study was carried out, through a questionnaire, to evaluate how many IBD patients received health education about vaccinations from the dedicated nurses (IBD nurses). RESULTS: There were four hundred questionnaires, 310 patients (77.5%) answered all questions. The nurse does not appear to help educate patients on influenza vaccination (66.1%) or pneumococcal vaccination (81.6%). Disclosed patients have many doubts about the new COVID-19 vaccination (74.4%) and many seek information (74.8%) and think that the nurse can provide the necessary information (70%). CONCLUSIONS: IBD nurses do not seem very active in the vaccination education role, and they do not meet patients’ expectations, which are conversely very high.
- Published
- 2021
36. Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report
- Author
-
Pugliese, D., Schepis, Tommaso, Bove, Vincenzo, Privitera, G., Boskoski, Ivo, Armuzzi, Alessandro, Schepis T., Bove V., Boskoski I. (ORCID:0000-0001-8194-2670), Armuzzi A. (ORCID:0000-0003-1572-0118), Pugliese, D., Schepis, Tommaso, Bove, Vincenzo, Privitera, G., Boskoski, Ivo, Armuzzi, Alessandro, Schepis T., Bove V., Boskoski I. (ORCID:0000-0001-8194-2670), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
N/A
- Published
- 2021
37. Predictors and early markers of response to biological therapies in inflammatory bowel diseases
- Author
-
Privitera, Giuseppe, Pugliese, Daniela, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Guidi, Luisa, Privitera G., Pugliese D., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Guidi L. (ORCID:0000-0003-3320-7094), Privitera, Giuseppe, Pugliese, Daniela, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Guidi, Luisa, Privitera G., Pugliese D., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), and Guidi L. (ORCID:0000-0003-3320-7094)
- Abstract
Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gas-trointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogene-ity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immuno-logical, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.
- Published
- 2021
38. Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
- Author
-
Privitera, G., Pugliese, D., Onali, S., Petito, V., Scaldaferri, F., Gasbarrini, A., Danese, S., Armuzzi, A., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, G., Pugliese, D., Onali, S., Petito, V., Scaldaferri, F., Gasbarrini, A., Danese, S., Armuzzi, A., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Background: Combining immunosuppressors has been proposed as a strategy to enhance treatment efficacy in Inflammatory Bowel Disease (IBD). Aim: To summarize current evidence on combinations of targeted therapies with traditional immunosuppressors or with other targeted therapies. Methods: A literature search on PubMed and Medline databases was performed to identify relevant articles. Results: Current evidence supports that the combination of infliximab and thiopurines is more effective than monotherapy with both agents in inducing remission in Crohn's Disease and Ulcerative colitis. Data on other combinations of other biologics and traditional immunosuppressors is lacking or show conflicting results. Vedolizumab seems a potentially effective maintenance regimen after calcineurin inhibitors-based rescue therapy in acute severe ulcerative colitis, as an alternative to thiopurines. Dual Targeted Therapy, which is the combination of 2 targeted therapies, might be a reasonable choice in patients with concomitant IBD and extraintestinal manifestations, or in patients with medical-refractory IBD who lack valid alternatives. Combinations with thiopurines are associated with an increased risk of infections and lymphoma. Data on other combinations is scarcer, but no specific safety issue has emerged so far. Conclusions: Combination therapies seem to be effective in selected patients, with an overall acceptable safety profile.
- Published
- 2021
39. Orphan patients with inflammatory bowel disease - when we treat beyond evidence
- Author
-
Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Papa, Alfredo, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Papa A. (ORCID:0000-0002-4186-7298), Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Papa, Alfredo, Rapaccini, Gian Ludovico, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Papa A. (ORCID:0000-0002-4186-7298), Rapaccini G. L. (ORCID:0000-0002-6467-857X), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Inflammatory bowel disease (IBD) is a chronic condition that requires continuous medical treatment. To date, the medical management of patients with moderately-to-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs. Such therapies are licenced after passing through three phases of randomized controlled trials (RCTs), and are subsequently adopted in clinical practice. However, the real-life population of IBD patients who require these therapies can significantly differ from those included in RCTs. As a matter of fact, there is a number of exclusion criteria – nearly ubiquitous in all RCTs – that prevent the enrolment of specific patients: Chronic refractory pouchitis or isolated proctitis in ulcerative colitis, short-bowel syndrome and stomas in Crohn’s disease, ileorectal anastomosis in both ulcerative colitis and Crohn’s disease, and elderly age are some representative examples. In this frontier article, we aim to give an overview of current literature on this topic, in order to address the main knowledge gaps that need to be filled in the upcoming years.
- Published
- 2021
40. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
- Author
-
Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Neri, Maria Luisa, Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Neri M., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Pugliese, Daniela, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Neri, Maria Luisa, Guidi, Luisa, Gasbarrini, Antonio, Armuzzi, Alessandro, Privitera G., Pugliese D., Lopetuso L. R., Scaldaferri F. (ORCID:0000-0001-8334-7541), Neri M., Guidi L. (ORCID:0000-0003-3320-7094), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.
- Published
- 2021
41. Personalized clinical phenotyping through systems medicine and artificial intelligence
- Author
-
Cesario, Alfredo, D'Oria, M., Bove, F., Privitera, G., Boskoski, Ivo, Pedicino, Daniela, Boldrini, Luca, Erra, Carmen, Loreti, Claudia, Liuzzo, Giovanna, Crea, Filippo, Armuzzi, Alessandro, Gasbarrini, Antonio, Calabresi, Paolo, Padua, Luca, Costamagna, Guido, Antonelli, Massimo, Valentini, Vincenzo, Auffray, C., Scambia, Giovanni, Cesario A. (ORCID:0000-0003-4687-0709), Boskoski I. (ORCID:0000-0001-8194-2670), Pedicino D., Boldrini L., Erra C., Loreti C., Liuzzo G. (ORCID:0000-0002-5714-0907), Crea F. (ORCID:0000-0001-9404-8846), Armuzzi A. (ORCID:0000-0003-1572-0118), Gasbarrini A. (ORCID:0000-0002-7278-4823), Calabresi P. (ORCID:0000-0003-0326-5509), Padua L. (ORCID:0000-0003-2570-9326), Costamagna G. (ORCID:0000-0002-8100-2731), Antonelli M. (ORCID:0000-0003-3007-1670), Valentini V. (ORCID:0000-0003-4637-6487), Scambia G. (ORCID:0000-0003-2758-1063), Cesario, Alfredo, D'Oria, M., Bove, F., Privitera, G., Boskoski, Ivo, Pedicino, Daniela, Boldrini, Luca, Erra, Carmen, Loreti, Claudia, Liuzzo, Giovanna, Crea, Filippo, Armuzzi, Alessandro, Gasbarrini, Antonio, Calabresi, Paolo, Padua, Luca, Costamagna, Guido, Antonelli, Massimo, Valentini, Vincenzo, Auffray, C., Scambia, Giovanni, Cesario A. (ORCID:0000-0003-4687-0709), Boskoski I. (ORCID:0000-0001-8194-2670), Pedicino D., Boldrini L., Erra C., Loreti C., Liuzzo G. (ORCID:0000-0002-5714-0907), Crea F. (ORCID:0000-0001-9404-8846), Armuzzi A. (ORCID:0000-0003-1572-0118), Gasbarrini A. (ORCID:0000-0002-7278-4823), Calabresi P. (ORCID:0000-0003-0326-5509), Padua L. (ORCID:0000-0003-2570-9326), Costamagna G. (ORCID:0000-0002-8100-2731), Antonelli M. (ORCID:0000-0003-3007-1670), Valentini V. (ORCID:0000-0003-4637-6487), and Scambia G. (ORCID:0000-0003-2758-1063)
- Abstract
Personalized Medicine (PM) has shifted the traditional top-down approach to medicine based on the identification of single etiological factors to explain diseases, which was not suitable for explaining complex conditions. The concept of PM assumes several interpretations in the literature, with particular regards to Genetic and Genomic Medicine. Despite the fact that some disease-modifying genes affect disease expression and progression, many complex conditions cannot be understood through only this lens, especially when other lifestyle factors can play a crucial role (such as the environment, emotions, nutrition, etc.). Personalizing clinical phenotyping becomes a challenge when different pathophysiological mechanisms underlie the same manifestation. Brain disorders, cardiovascular and gastroentero-logical diseases can be paradigmatic examples. Experiences on the field of Fondazione Policlinico Gemelli in Rome (a research hospital recognized by the Italian Ministry of Health as national leader in “Personalized Medicine” and “Innovative Biomedical Technologies”) could help understanding which techniques and tools are the most performing to develop potential clinical phenotypes person-alization. The connection between practical experiences and scientific literature highlights how this potential can be reached towards Systems Medicine using Artificial Intelligence tools.
- Published
- 2021
42. Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy
- Author
-
Privitera, Giuseppe, Pugliese, Daniela, Scaldaferri, Franco, Armuzzi, Alessandro, Privitera G., Pugliese D., Scaldaferri F. (ORCID:0000-0001-8334-7541), Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Pugliese, Daniela, Scaldaferri, Franco, Armuzzi, Alessandro, Privitera G., Pugliese D., Scaldaferri F. (ORCID:0000-0001-8334-7541), and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
N/A
- Published
- 2021
43. Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
- Author
-
Privitera, Giuseppe, Pugliese, Daniela, Onali, Sebastiano, Petito, Valentina, Scaldaferri, Franco, Gasbarrini, Antonio, Danese, Silvio, Armuzzi, Alessandro, Privitera G., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., Armuzzi A. (ORCID:0000-0003-1572-0118), Privitera, Giuseppe, Pugliese, Daniela, Onali, Sebastiano, Petito, Valentina, Scaldaferri, Franco, Gasbarrini, Antonio, Danese, Silvio, Armuzzi, Alessandro, Privitera G., Pugliese D., Onali S., Petito V., Scaldaferri F. (ORCID:0000-0001-8334-7541), Gasbarrini A. (ORCID:0000-0002-7278-4823), Danese S., and Armuzzi A. (ORCID:0000-0003-1572-0118)
- Abstract
Background: Combining immunosuppressors has been proposed as a strategy to enhance treatment efficacy in Inflammatory Bowel Disease (IBD). Aim: To summarize current evidence on combinations of targeted therapies with traditional immunosuppressors or with other targeted therapies. Methods: A literature search on PubMed and Medline databases was performed to identify relevant articles. Results: Current evidence supports that the combination of infliximab and thiopurines is more effective than monotherapy with both agents in inducing remission in Crohn's Disease and Ulcerative colitis. Data on other combinations of other biologics and traditional immunosuppressors is lacking or show conflicting results. Vedolizumab seems a potentially effective maintenance regimen after calcineurin inhibitors-based rescue therapy in acute severe ulcerative colitis, as an alternative to thiopurines. Dual Targeted Therapy, which is the combination of 2 targeted therapies, might be a reasonable choice in patients with concomitant IBD and extraintestinal manifestations, or in patients with medical-refractory IBD who lack valid alternatives. Combinations with thiopurines are associated with an increased risk of infections and lymphoma. Data on other combinations is scarcer, but no specific safety issue has emerged so far. Conclusions: Combination therapies seem to be effective in selected patients, with an overall acceptable safety profile.
- Published
- 2021
44. Challenges in crohn’s disease management after gastrointestinal cancer diagnosis
- Author
-
Fiorillo, Claudio, Schena, Carlo Alberto, Quero, Giuseppe, Laterza, Vito, Pugliese, D., Privitera, G., Rosa, Fausto, Schepis, Tommaso, Salvatore, Lisa, Di Stefano, B., Larosa, Luigi, Minordi, Laura Maria, Natale, Luigi, Tortora, Giampaolo, Armuzzi, Alessandro, Alfieri, Sergio, Fiorillo C. (ORCID:0000-0001-7681-3567), Schena C. A., Quero G. (ORCID:0000-0002-0001-9479), Laterza V., Rosa F. (ORCID:0000-0002-7280-8354), Schepis T., Salvatore L., Larosa L., Minordi L. M., Natale L. (ORCID:0000-0002-7949-5119), Tortora G. (ORCID:0000-0002-1378-4962), Armuzzi A. (ORCID:0000-0003-1572-0118), Alfieri S. (ORCID:0000-0002-0404-724X), Fiorillo, Claudio, Schena, Carlo Alberto, Quero, Giuseppe, Laterza, Vito, Pugliese, D., Privitera, G., Rosa, Fausto, Schepis, Tommaso, Salvatore, Lisa, Di Stefano, B., Larosa, Luigi, Minordi, Laura Maria, Natale, Luigi, Tortora, Giampaolo, Armuzzi, Alessandro, Alfieri, Sergio, Fiorillo C. (ORCID:0000-0001-7681-3567), Schena C. A., Quero G. (ORCID:0000-0002-0001-9479), Laterza V., Rosa F. (ORCID:0000-0002-7280-8354), Schepis T., Salvatore L., Larosa L., Minordi L. M., Natale L. (ORCID:0000-0002-7949-5119), Tortora G. (ORCID:0000-0002-1378-4962), Armuzzi A. (ORCID:0000-0003-1572-0118), and Alfieri S. (ORCID:0000-0002-0404-724X)
- Abstract
Crohnʹs disease (CD) is a chronic inflammatory bowel disease with a progressive course, potentially affecting the entire gastrointestinal tract from mouth to anus. Several studies have shown an increased risk of both intestinal and extra‐intestinal cancer in patients with CD, due to long‐standing transmural inflammation and damage accumulation. The similarity of symptoms among CD, its related complications and the de novo onset of gastrointestinal cancer raises difficulties in the differential diagnosis. In addition, once a cancer diagnosis in CD patients is made, selecting the appropriate treatment can be particularly challenging. Indeed, both surgical and oncological treatments are not always the same as that of the general population, due to the inflammatory context of the gastrointestinal tract and the potential exacerbation of gastrointestinal symptoms of patients with CD; moreover, the overlap of the neoplastic disease could lead to adjustments in the pharmacological treatment of the underlying CD, especially with regard to immunosuppressive drugs. For these reasons, a case‐by‐case analysis in a multidisciplinary approach is often appropriate for the best diagnostic and therapeutic evaluation of patients with CD after gastrointestinal cancer onset.
- Published
- 2021
45. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis
- Author
-
Roberto Cangemi, Valeria Raparelli, Giovanni Talerico, Stefania Basili, Francesco Violi, Palasciano Giuseppe, D’Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Sacerdoti David, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Perticone Francesco, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Andriulli Angelo, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Raimondo Giovanni, Maimone Sergio, Cacciola Irene, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Picardi Antonio, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davì Giovanni, Schiavone Cosima, Santilli Francesca, Tana Claudio, Licata Anna, Soresi Maurizio, Bianchi Giovanni Battista, Carderi Isabella, Pinto Antonio, Tuttolomondo Antonino, Ferrari Giovanni, Gresele Paolo, Fierro Tiziana, Morelli Olivia, Laffi Giacomo, Romanelli Roberto Giulio, Arena Umberto, Stasi Cristina, Gasbarrini Antonio, Gargovich Matteo, Zocco Maria Assunta, Riccardi Laura, Ainora Maria Elena, Capeci William, Martino Giuseppe Pio, Nobili Lorenzo, Cavallo Maurizio, Frugiuele Pierluigi, Greco Antonio, Pietrangelo Antonello, Ventura Paolo, Cuoghi Chiara, Marcacci Matteo, Serviddio Gaetano, Vendemiale Gianluigi, Villani Rosanna, Gargano Ruggiero, Vidili Gianpaolo, Di Cesare Valentina, Masala Maristella, Delitala Giuseppe, Invernizzi Pietro, Di Minno Giovanni, Tufano Antonella, Purrello Francesco, Privitera Graziella, Forgione Alessandra, Curigliano Valentina, Senzolo Marco, Rodríguez-Castro Kryssia Isabel, Giannelli Gianluigi, Serra Carla, Neri Sergio, Pignataro Pietro, Rizzetto Mario, Debernardi Venon Wilma, Svegliati Baroni Gianluca, Bergamaschi Gaetano, Masotti Michela, Costanzo Filippo, Corazza Gino Roberto, Caldwell Stephen Hugh, Angelico Francesco, Del Ben Maria, Napoleone Laura, Polimeni Licia, Proietti Marco, Raparelli Valeria, Romiti Giulio Francesco, Ruscio Eleonora, Severoni Andrea, Talerico Giovanni, Toriello Filippo, and Vestri Annarita
- Subjects
Albumin ,Cirrhosis ,Portal Vein Thrombosis ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background and Aims: Hypoalbuminemia, as defined by serum albumin (SA) levels ≤35 g/L, is associated to venous and arterial thrombosis in general population and in patients at risk of cardiovascular disease. It is unknown if SA ≤35 g/L is also associated to portal vein thrombosis (PVT) in cirrhosis. Methods: Cirrhotic patients enrolled in the Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry (PRO-LIVER) study (n = 753), were followed-up for 2 years to assess the risk of PVT, that was diagnosed by Doppler ultrasonography. Child-Pugh classes, Model for End-Stage Liver Disease score, presence of hepatocellular carcinoma and laboratory variables including SA, D-dimer, and high-sensitivity C-reactive protein (hs-CRP) were measured at baseline. Results: SA ≤35 g/L was detected in 52% of patients. A logistic multivariate regression analysis showed that higher Child-Pugh class, hepatocellular carcinoma and thrombocytopenia were significantly associated to SA ≤35 g/L. In a subgroup of patients where data regarding hs-CRP and D-dimer were available, SA ≤35 g/L was inversely associated with hs-CRP and D-dimer. During the follow-up, a total of 61 patients experienced PVT. A Kaplan Meier survival analysis showed SA ≤35 g/L was associated to increased risk of PVT compared to SA >35 g/L (P = .005). A multivariate Cox proportional hazards regression analysis showed that male sex, lower platelet count, and SA ≤35 g/L remained associated to PVT after adjusting for confounding factors. Conclusion: Cirrhotic patients with SA ≤35 g/L are at higher risk of experiencing PVT compared to those with SA >35 g/L and could be considered as potential candidates to anticoagulant prophylaxis for PVT prevention.
- Published
- 2024
- Full Text
- View/download PDF
46. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
- Author
-
Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., and Castorina, S.
- Published
- 2014
- Full Text
- View/download PDF
47. Erice 2018 Charter on the role of the National Health Service in the prevention of doping
- Author
-
Romano Spica, V., Di Rosa, E., Savino, G., Pasquarella, C., Liguori, G., Fallace, P., Tripi, F., Fara, G. M., Giammanco, G., Abbafati, E., Alonzo, E., Agostini, D., Aini, M. A., Ajese, P., Amore, G., Antonuccio, G., Assisi, E., Attisani, G., Belfiore, P., Belotti, D., Bernieri, F., Bernini, D., Bolognini, I., Bono, R., Brandimarte, M. A., Buzancic, S., Cala, P., Cagnin, R., Capua, G., Caruso, L., Cattaruzza, M. S., Cella, P., Ciotti, L., Cipolla, A. M., Colucci, M. E., Coppola, L., Covacci, V., Creola, G., Culcasi, S., D'Alterio, A., De Santi, M., Di Benedetto, F., Di Onofrio, V., Donati, A., Dozzini, G., Esposito, R., Fabbro, A., Falcone, M., Fara, T., Fardella, M., Favuzzi, N., Fioretti, E., Frangella, C., Galle, F., Ghizzoni, D., Giampietro, M., Giorgino, A., Grillone, L., Gradilone, A., Greco, S., Grosso, G., Guberti, E., Guida, F., La Carruba, R., La Sala, L., Cadua, E., Landi, A., Lemma, P., Leonardi, F., Lusi, A., Manfredi Selvaggi, T. M., Mandina, G., Marini, S., Mazzeo, F., Menegon, T., Mete, R., Milicia, M. G., Morgado, M., Morgantini, F., Napoli, M., Nucera, S., Occhipinti, V., Orsini, M., Pacella, G., Pacifici, R., Palmi, I., Pandolfi, R., Parisi, A., Parodi, G., Parodi, S., Pasquarella, M. L., Persi, Y., Petrai, G., Petrella, E., Pinelli, M., Pompei, D., Pompili, M., Postiglione, N., Ripani, M., Romano, F., Rondinelli, L., Ricchiuti, R., Ruggeri, J., Santini, A., Scatigna, M., Scuderi, M., Signorelli, C., Sticchi, C., Tamarri, F., Tancredi, S., Tumbarello, A., Ursino, S., Valeriani, F., Vino, F., Zanetti, C., Zotta, I., Zucca, E., Calimeri, S., Privitera, G., Fabiani, L., D'Aloisio, F., Baccari, G., Leoni, E., Tafuri, S., Brandi, G., Gervasi, G., Dell'Eva, A., La Torre, A., Romano Spica, V., Di Rosa, E., Savino, G., Pasquarella, C., Liguori, G., Fallace, P., Tripi, F., Fara, G. M., Giammanco, G., Abbafati, E., Alonzo, E., Agostini, D., Aini, M. A., Ajese, P., Amore, G., Antonuccio, G., Assisi, E., Attisani, G., Belfiore, P., Belotti, D., Bernieri, F., Bernini, D., Bolognini, I., Bono, R., Brandimarte, M. A., Buzancic, S., Calà, P., Cagnin, R., Capua, G., Caruso, L., Cattaruzza, M. S., Cella, P., Ciotti, L., Cipolla, A. M., Colucci, M. E., Coppola, L., Covacci, V., Creola, G., Culcasi, S., D'Alterio, A., De Santi, M., Di Benedetto, F., Di Onofrio, V., Donati, A., Dozzini, G., Esposito, R., Fabbro, A., Falcone, M., Fara, T., Fardella, M., Favuzzi, N., Fioretti, E., Frangella, C., Gallè, F., Ghizzoni, D., Giampietro, M., Giorgino, A., Grillone, L., Gradilone, A., Greco, S., Grosso, G., Guberti, E., Guida, F., La Carruba, R., La Sala, L., Cadua, E., Landi, A., Lemma, P., Leonardi, F., Lusi, A., Manfredi Selvaggi, T. M., Mandina, G., Marini, S., Mazzeo, F., Menegon, T., Mete, R., Milicia, M. G., Morgado, M., Morgantini, F., Napoli, M., Nucera, S., Occhipinti, V., Orsini, M., Pacella, G., Pacifici, R., Palmi, I., Pandolfi, R., Parisi, A., Parodi, G., Parodi, S., Pasquarella, M. L., Persi, Y., Petrai, G., Petrella, E., Pinelli, M., Pompei, D., Pompili, M., Postiglione, N., Ripani, M., Romano, F., Rondinelli, L., Ricchiuti, R., Ruggeri, J., Santini, A., Scatigna, M., Scuderi, M., Signorelli, C., Sticchi, C., Tamarri, F., Tancredi, S., Tumbarello, A., Ursino, S., Valeriani, F., Vino, F., Zanetti, C., Zotta, I., Zucca, E., Calimeri, S., Privitera, G., Fabiani, L., D'Aloisio, F., Baccari, G., Leoni, E., Tafuri, S., Brandi, G., Gervasi, G., Dell'Eva, A., and La Torre, A.
- Subjects
Doping in Sports ,Health Promotion ,Humans ,Italy ,State Medicine ,Public Health ,Department of Prevention ,Doping ,Physical Activity ,Sport ,Doping, Health Promotion, Physical Activity, Sport, Department of Prevention - Abstract
The Erice 2018 Charter was unanimously approved at the conclusion of the 53rd Residential Course of the International School of Epidemiology and Preventive Medicine “Adapted Physical Activity in Sport, Wellness and Fitness; the role of the Departments of Prevention and of the National Health Service in doping prevention and health promotion”, held on 15-19 May 2018 in Erice, Italy, at the “Ettore Majorana” Foundation and Centre for Scientific Culture, and promoted by the Study Group on “Movement Sciences for Health” of the Italian Society of Hygiene, Preventive Medicine and Public Health. The event was part of a larger project supported by the Ministry of Health aimed at preventing doping in the general population involved in sport and physical activities. After an intense discussion the participants focused on ten statements involving the following critical issues: responsibility, priority, message, alphabetization, networks and alliances, school promoting health, player and opportunities, competences, know-how, programming and acting. These statements provide hints to approach doping within a public health frame and summarize the role of the Departments of Prevention and NHS in promoting and coordinating preventive actions with other institutions and stakeholders. Doping represents a complex phenomenon related to cultural, social, economic and legal issues. In addition to regulatory or repressive actions, education to health and legality is proposed as the fundamental strategy to contrast doping by promoting healthy lifestyles, based on scientific knowledge and respect for legality.
- Published
- 2019
48. The prevention of doping and the improper use of drugs and food supplements in sports and physical activities: a survey on the activity of the prevention departments of Italian local health authorities
- Author
-
Pasquarella, C., Pompili, M., Valeriani, F., Morgado, M., Milicia, G. M., Veronesi, L., Odone, A., Zoni, R., Saccani, E., Savino, G., Persi, Y., Pinelli, M., Liguori, G., Galle, F., Di Onofrio, V., Fallace, P., Romano Spica, V., Calimeri, S., Bono, R., Privitera, G., Fabiani, L., D'Aloisio, F., Baccari, G., Leoni, E., Tafuri, S., Brandi, G., Gervasi, G., Dell'Eva, A., Gradilone, A., Frangella, C., La Torre, A., Trenti, T., Agostini, D., Aini, M. A., Alonzo, E., Assisi, E., Belotti, D., Cagnin, R., Coppola, L., Giorgino, A., Libardi, L., Manfredi Selvaggi, T. M., Morgantini, F., Parodi, G., Pompei, D., Santini, I., Sticchi, C., Ursino, S., Pasquarella C., Pompili M., Valeriani F., Morgado M., Milicia G.M., Veronesi L., Odone A., Zoni R., Saccani E., Savino G., Persi Y., Pinelli M., Liguori G., Galle F., Di Onofrio V., Fallace P., Romano Spica V., Calimeri S., Bono R., Privitera G., Fabiani L., D'Aloisio F., Baccari G., Leoni E., Tafuri S., Brandi G., Dell'Eva A., Gradilone A., Frangella C., and La Torre A.
- Subjects
Doping in Sports ,Prevention departments, doping, food supplements, drugs, prevention, health promotion ,Prevention ,Doping ,Drugs ,Food supplements ,Health promotion ,Prevention departments ,Food supplement ,Health Promotion ,drugs ,State Medicine ,food supplements ,Italy ,Athletes ,Surveys and Questionnaires ,Dietary Supplements ,Humans ,Public Health ,Drug ,human activities - Abstract
Introduction. Doping is an important public health problem widespread not only among elite athletes, but also among amateur and recreational athletes and the general population. In Italy the introduction of doping prevention within the Essential Levels of Care (LEA) with the DPCM 12/1/2017 represents a crucial step towards the implementation of education and health promotion interventions. In this context, the Departments of Prevention (DP) of the Local Health Authorities (LHA) have to play a fundamental role, becoming the cultural and operational reference on this issue. As part of the "Doping prevention: development of a permanent educational tool coordinated by the National Health Service Prevention Departments" project, funded by the Italian Ministry of Health, a survey was conducted on the activities carried out by the DP regarding doping prevention and improper use and abuse of drugs and food supplements in sports and physical activities, as a basis for the harmonization of organizational structures and prevention programs and the creation of a collaboration network at a regional and national level.Methods. A semi-structured questionnaire consisting of 11 questions, prepared on an electronic platform, was sent to the DP of all the Italian LHA.Results. A total of 38 DP out of 131 (29%) completed the questionnaire, with representation from all regions. 42.1% of DP carried out or are still running programs for the prevention of doping, a percentage that decreases to 27% considering the programs for the prevention of misuse and abuse of drugs and food supplements in sports and in physical activities; in less than half of the DP, 37.5% and 41.7%, respectively, dedicated funds have been allocated. The professionals most involved in prevention of doping are the Specialists in Sport Medicine (81.3%) followed by Specialists in Hygiene (43.8%) and Psychologists (37.5%), while Health Care Assistants (50%) are the professionals most involved in the prevention of the improper use of drugs and food supplements, followed by Specialists in Hygiene and Specialists in Sport Medicine (40%). Most of the DP (71.9%) believe that the introduction of programs to prevent and counteract doping in the LEA will have repercussions on their approach against doping.Conclusions. The survey, although conducted on a limited sample, has provided an important framework relating to programs for the prevention of doping and the misuse and abuse of drugs and food supplements in sports and in the physical activities carried out by DP A remarkable heterogeneity has been highlighted, both at national and regional level. It is urgent to provide DP with homogeneous and effective organizational models and adequate operational tools, paying particular attention to the training of all the professionals involved. It is also essential to implement permanent monitoring tools.
- Published
- 2019
49. Use of hormones in doping and cancer risk
- Author
-
De Santi, M, Baldelli, G, Brandi, G, Calimeri, S., Bono, R., Privitera, G., Fabiani, L., D'Aloisio, F., Baccari, G., Leoni, E., Tafuri, S., Liguori, G., Brandi, G., Gervasi, G., Dell'Eva, A., Gradilone, A., Frangella, C., La Torre, A., Romano Spica, V., Trenti, T., Pasquarella, C., Fallace, P., De Santi M., Baldelli G., Brandi G., Baccari G., Bono R., Calimeri S., D'Aloisio F, Dell'Eva A., Fabiani L., Frangella C., Gervasi G., Gradilone A., La Torre A., Leoni E., Liguori G., Privitera G., and Tafuri S.
- Subjects
Doping in Sports ,Risk ,Human Growth Hormone ,Substance-Related Disorders ,Cancer Parole chiave: Ormone della crescita ,Cancro ,Doping ,Growth hormone ,IGF-1 ,doping ,Athletes ,Disease Progression ,Humans ,Insulin-Like Growth Factor I ,Neoplasms ,Growth hormone, IGF-1, doping, cancer ,cancer - Abstract
Hormones with anabolic properties such as growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are commonly abused among professional and recreational athletes to enhance physical ability. Despite their adverse effects are well-documented, the use of GH and IGF-1 has recently grown. This article highlights the anabolic activity related to mechanisms of cancer development and progression. GH/IGF-1 axis is able to activate cellular mechanisms that modulate every key stage of cancer formation and progression, such as inhibition of apoptosis, resistance to treatments, and induction of angiogenesis, metastatic process and cell proliferation. Results from pre-clinical studies and epidemiological observations in patients with an excess of GH and IGF-1 production or treated with these hormones showed a positive association with the risk to develop several types of cancer. In conclusion, athletes should be made aware that long-term treatment with doping agents might increase the risk of developing cancer, especially if associated with other licit or illicit drugs and/or high-protein diet.
- Published
- 2019
50. Exploring the association between physical activity and gut microbiota composition: a review of current evidence
- Author
-
Gallè, F., Valeriani, F., Cattaruzza, M. S., Ubaldi, F., Romano Spica, V., Liguori, G., GSMS-SItI, Calimeri, S., Bono, R., Privitera, G., Fabiani, L., D’Aloisio, F., Baccari, G., Leoni, E., Tafuri, S., Brandi, G., Gervasi, G., Dell’Eva, A., Gradilone, A., Frangella, C., La Torre, A., Galle F., Valeriani F., Cattaruzza M.S., Ubaldi F., Romano Spica V., Liguori G., Baccari G., Bono R., Calimeri S., D'Aloisio F, Dell'Eva A., Fabiani L., Frangella C., Gerais G., Gradilone A., La Torre A., Leoni E., Privitera G., and Tafuri S.
- Subjects
Bacteroidetes ,Health ,Animals ,Firmicutes ,Humans ,Gut Microbiota, Health, Physical Activity, Exercise ,Physical Activity ,Gut Microbiota ,digestive system ,Exercise ,Diet ,Gastrointestinal Microbiome - Abstract
The gut microbiota is implicated in digestive, metabolic and immune processes of the host. The physiological and pathophysiological functions of the intestinal microbiota depend of its composition, and several individual or external factors may be associated with the presence of some categories, phyla or species of microorganisms in the gut. In particular, two bacterial phyla - Firmicutes and Bacteroidetes - are predominant in the human gut and their relative concentrations seem to be related with age, gender, diet habits and weight status. In the last decade, several studies have tried to characterize the possible role of physical activity in determining qualitative and quantitative composition of the intestinal microbiota. This review is aimed at exploring the current evidences regarding the association between physical activity and gut microbiota composition in animal models and in the humans. Further studies are needed to clarify the mutual relationships among exercise, diet, nutritional supplements/doping agents and gut microbiota.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.